Clinical proteomics reveals vulnerabilities in non-invasive breast ductal carcinoma and drives personalized treatment strategies.
G. Mitsa, L. Florianova, J. Lafleur, A. Aguilar-Mahecha, R. P. Zahedi, S. V. Del Rincon, M. Basik, C. H. Borchers, G. Batist
The paper uses clinical proteomics to identify biomarkers and metabolic vulnerabilities in DCIS, informing therapeutic strategies and developing a targeted proteomics assay for cancer-related pathways.
bioRxiv · Jul 11, 2023 · PreprintCancer Biology